

## ASX Announcement

### Imugene hosts investigator meeting for gastric cancer clinical trial

**MELBOURNE Australia 9 February 2018:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company will host a meeting of investigators involved in the current clinical trial of its HER-Vaxx (IMU 131) cancer vaccine on Sunday 11 February 2018 in Bangkok Thailand.

The meeting brings together investigators from all trial sites in Hong Kong, Thailand and Taiwan to share and discuss their experience recruiting and results of treating the unmet medical needs of patients with metastatic gastric cancer and review early data from the current Phase 1b trial of the HER-Vaxx cancer therapy.

The current trial seeks to confirm tolerability and safety of the treatment as well as identify optimal dosing in combination with chemotherapy to prolong survival in patients with metastatic gastric cancer.

The meeting will feature presentations by HER-Vaxx inventors Professor Dr. Christoph Zielinski and Professor Dr. Ursula Wiedermann who will provide a detailed review of the clinical data to date.

On 7 February, Imugene said researchers had reported no safety, toxicity or tolerability issues with HER-Vaxx during the first cohort dosing of patients.

Imugene Chief Executive Officer Leslie Chong will provide a strategic update and overview of plans to build on the work to date and expand Imugene's clinical pipeline.

Lead investigator Professor Dr. Christoph Zielinski is Chairman of the Comprehensive Cancer Centre in Vienna, Chairman of the Centre for Eastern European Organisation for Research and Treatment of Cancer. He is also Editor in Chief and President nominee of the European Society of Medical Oncology (ESMO).

Professor Dr. Ursula Wiedermann is the Chief Scientific Officer of Imugene and co-inventor of HER-Vaxx. Among many other titles she is Professor of Vaccinology at the Medical University of Vienna.

HER-Vaxx works by targeting the same cancer cell receptors as two widely used antibody drugs, Herceptin® and Perjeta®, marketed by Swiss multinational Roche.

Clinical results to date indicate the therapy induces strong immune responses in patients, with antibodies to the target cancer biomarker HER2/neu strongly evident in validated assays.

For further information please contact:

Leslie Chong  
Chief Executive Officer  
E: Leslie.Chong@Imugene.com

### **About Imugene (ASX:IMU)**

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.